초록 ▼

Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when

Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.

대표청구항 ▼

What is claimed is: 1. A dried hemoactive material for inhibiting bleeding or delivering an agent, comprising: a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood; and a non-cross-linked biologically compatible polymer which solubilizes when exposed to blood:

What is claimed is: 1. A dried hemoactive material for inhibiting bleeding or delivering an agent, comprising: a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood; and a non-cross-linked biologically compatible polymer which solubilizes when exposed to blood: wherein the cross-linked polymer is dispersed in a dried matrix of the non-cross-linked polymer. 2. A material as in claim 1, wherein the cross-linked polymer is a protein selected from the group consisting of gelatin, collagen, albumin, hemoglobin, fibrinogen, fibrin, fibronectin, elastin, keratin, laminin, and casein. 3. A material as in claim 1, wherein the cross-linked polymer is a carbohydrate or carbohydrate derivative selected from the group consisting of glycosaminglycans, starches, celluloses, hemicelluloses, xylan, agarose, alginate, and chitosan. 4. A material as in claim 1, wherein the cross-linked polymer is a non-biologic hydrogel-forming polymer or copolymer selected from the group consisting of polyacrylates, polymethacrylates, polyacrylamides, polyvinyl polymers, polylactides-glycolides, polycaprolactones, polyoxyethelenes, and copolymers thereof. 5. A material as in claim 1, wherein the non-cross-linked biologically compatible polymer is a protein selected from the group consisting of gelatin, collagen, albumin, elastin, and keratin. 6. A material as in claim 1, wherein the non-cross-linked biologically compatible polymer is a carbohydrate or carbohydrate derivative selected from the group consisting of glycosaminoglycans, alginate, starch, cellulose, and derivatives thereof. 7. A dried hemoactive material for inhibiting bleeding or delivering an agent, comprising: a non-cross-linked polymer comprising a dry gelatin matrix; and dry, cross-linked gelatin polymer particles dispersed in the dry non-cross-linked gelatin matrix. 8. A material as in claim 1 or 7, wherein the cross-linked polymer has a degradation time of at least one day. 9. A material as in claim 1 or 7, wherein the non-cross-linked polymer solubilizes in 15 minutes or less when exposed to blood. 10. A material as in claim 1 or 7, wherein the cross-linked polymer is fragmented so that, upon hydration in blood, the polymer will form a gel with a sub-unit size in the range from 0.01 mm to 5 mm. 11. A material as in claim 10, wherein the cross-linked polymer has an equilibrium swell in the range from 400% to 5,000%. 12. A material as in claim 1 or 7, in the form of a sheet having a thickness in the range from 1 mm to 75 mm. 13. A material as in claim 12, wherein the sheet is packed in a sterile pack. 14. A kit comprising: a sterile pack; a sterile sheet of material as in claim 12, packaged in the sterile pack; and instructions for use setting forth a method for inhibiting bleeding by placing the sterilized sheet of material over bleeding tissue. 15. A material as in claim 1 or 7, wherein the cross-linked polymer is present at from 50 weight % to 95 weight % of the material and the non-cross-linked material is present at from 50 weight % to 1 weight % of the material. 16. A material as in claim 15, further comprising a plasticizer present at from 1 weight % to 20 weight % of the material. 17. A material as in claim 16, wherein the plasticizer is present in at least the non-cross-linked polymer. 18. A material as in claim 17, wherein the plasticizer is selected from the group consisting of polyethylene glycol, sorbitol, and glycerol. 19. A material as in claim 1 or 7, further comprising an active agent. 20. A material as in claim 19, wherein the active agent is present in at least the non-cross-linked polymer. 21. A material as in claim 19, wherein the active agent is present in at least the cross-linked polymer. 22. A material as in claim 19, wherein the active agent is present in both the non-cross-linked polymer and the cross-linked polymer. 23. A material as in claim 19, wherein the active agent is selected from the group consisting of antibiotics, anti-neoplastic agents, bacteriostatic agents, bactericidal agents, antiviral agents, anesthetics, anti-inflammatory agents, hormones, anti-angiogenic agents, antibodies, enzymes, enzyme inhibitors, and neurotransmitters. 24. A method for delivering an active agent to a patient, said method comprising: applying the material of claim 19 to or near a target region of the patient. 25. A material as in claim 19, wherein the active agent is a hemostatic substance. 26. A method for inhibiting bleeding, said method comprising: applying the material of claim 25 to a wound site. 27. A material as in claim 25, wherein the hemostatic substance is a clotting factor. 28. A material as in claim 27, wherein the clotting factor is thrombin. 29. A method for making a hemoactive material, said method comprising: dissolving in an aqueous medium a non-cross-linked biologically compatible polymer which solubilizes when exposed to blood; suspending in said aqueous medium containing the non-cross-linked polymer a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood; and drying the resulting aqueous medium containing both polymers to form a solid phase comprising the cross-linked polymer in dry form dispersed in a dry matrix of the non-cross-linked polymer.